New generation of breast cancer clinical trials implementing molecular profiling

von Zardavas, Dimitrios, Piccart-Gebhart, Martine
Veröffentlicht in Cancer Biol Med (2016)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial

von De Angelis, Claudia, Ignatiadis, Michail, Piccart-Gebhart, Martine
Veröffentlicht in Ann Transl Med (2020)

How Long is Enough – Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

von Pinto, Ana Catarina, de Azambuja, Evandro, Piccart-Gebhart, Martine
Veröffentlicht 2013

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature

von Mokrim, Maha, Aftimos, Philippe G, Errihani, Hassan, Piccart-Gebhart, Martine
Veröffentlicht 2014

The MINDACT trial: The first prospective clinical validation of a genomic tool

von Cardoso, Fatima, Piccart-Gebhart, Martine, Veer, Laura Van't, Rutgers, Emiel
Veröffentlicht in Mol Oncol (2007)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

von Brandão, Mariana, Reyal, Fabien, Hamy, Anne-Sophie, Piccart-Gebhart, Martine
Veröffentlicht in ESMO Open (2019)

Targeting immune checkpoints in breast cancer: an update of early results

von Solinas, Cinzia, Gombos, Andrea, Latifyan, Sofiya, Piccart-Gebhart, Martine, Kok, Marleen, Buisseret, Laurence
Veröffentlicht in ESMO Open (2017)

What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?

von Brandão, Mariana, Caparica, Rafael, Malorni, Luca, Prat, Aleix, Carey, Lisa A., Piccart-Gebhart, Martine
Veröffentlicht in Clin Cancer Res (2020)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report

von Mhamdi, Hasnae Alaoui, Kourie, Hampig Raphael, Jungels, Christiane, Aftimos, Philippe, Belbaraka, Rhizlane, Piccart-Gebhart, Martine
Veröffentlicht in J Med Case Rep (2017)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

von Rossari, José R., Metzger-Filho, Otto, Paesmans, Marianne, Saini, Kamal S., Gennari, Alessandra, de Azambuja, Evandro, Piccart-Gebhart, Martine
Veröffentlicht 2012

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25

von Pinto, Ana Catarina, Ferreira-Santos, Fernando, Lago, Lissandra Dal, de Azambuja, Evandro, Pimentel, Francisco Luís, Piccart-Gebhart, Martine, Razavi, Darius
Veröffentlicht 2014

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

von Hunter, Francis W., Barker, Hilary R., Lipert, Barbara, Rothé, Françoise, Gebhart, Géraldine, Piccart-Gebhart, Martine J., Sotiriou, Christos, Jamieson, Stephen M. F.
Veröffentlicht in Br J Cancer (2019)

Targeted therapies in breast cancer: are heart and vessels also being targeted?

von Criscitiello, Carmen, Metzger-Filho, Otto, Saini, Kamal S, de Castro Jr, Gilberto, Diaz, Marie, La Gerche, André, de Azambuja, Evandro, Piccart-Gebhart, Martine J
Veröffentlicht 2012

Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?

von Burstein, Harold J., Piccart-Gebhart, Martine J., Perez, Edith A., Hortobagyi, Gabriel N., Wolmark, Norman, Albain, Kathy S., Norton, Larry, Winer, Eric P., Hudis, Clifford A.
Veröffentlicht in J Clin Oncol (2012)

Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer

von Liedtke, Cornelia, Hatzis, Christos, Symmans, William Fraser, Desmedt, Christine, Haibe-Kains, Benjamin, Valero, Vicente, Kuerer, Henry, Hortobagyi, Gabriel N., Piccart-Gebhart, Martine, Sotiriou, Christos, Pusztai, Lajos
Veröffentlicht 2009

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1year: a systematic review...

von Saad, Everardo D, Squifflet, Pierre, Burzykowski, Tomasz, Quinaux, Emmanuel, Delaloge, Suzette, Mavroudis, Dimitris, Perez, Edith, Piccart-Gebhart, Martine, Schneider, Bryan P, Slamon, Dennis, Wolmark, Norman, Buyse, Marc
Veröffentlicht in Lancet Oncol (2019)

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

von Bense, Rico D., Sotiriou, Christos, Piccart-Gebhart, Martine J., Haanen, John B. A. G., van Vugt, Marcel A. T. M., de Vries, Elisabeth G. E., Schröder, Carolien P., Fehrmann, Rudolf S. N.
Veröffentlicht in J Natl Cancer Inst (2016)

A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials

von de Azambuja, Evandro, Ponde, Noam, Procter, Marion, Rastogi, Priya, Cecchini, Reena, Lambertini, Matteo, Ballman, Karla, Aspitia, Alvaro Moreno, Zardavas, Dimitrios, Roca, Lise, Gelber, Richard D., Piccart-Gebhart, Martine, Suter, Thomas
Veröffentlicht in Breast Cancer Res Treat (2019)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral het...

von Viale, Giuseppe, Slaets, Leen, de Snoo, Femke A., Bogaerts, Jan, Russo, Leila, van’t Veer, Laura, Rutgers, Emiel J. T., Piccart-Gebhart, Martine J., Stork-Sloots, Lisette, Dell’Orto, Patrizia, Glas, Annuska M., Cardoso, Fatima
Veröffentlicht in Breast Cancer Res Treat (2016)

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

von Dowsett, Mitch, Procter, Marion, McCaskill-Stevens, Worta, de Azambuja, Evandro, Dafni, Urania, Rueschoff, Josef, Jordan, Bruce, Dolci, Stella, Abramovitz, Mark, Stoss, Oliver, Viale, Giuseppe, Gelber, Richard D., Piccart-Gebhart, Martine, Leyland-Jones, Brian
Veröffentlicht 2009